The latest price target for Oramed Pharmaceuticals (NASDAQ:ORMP) was reported by HC Wainwright & Co. on September 9, 2024. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Oramed Pharmaceuticals (NASDAQ:ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals reiterated their neutral rating.

There is no last upgrade for Oramed Pharmaceuticals

The last downgrade for Oramed Pharmaceuticals Inc happened on January 17, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Oramed Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a reiterated with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.22, which is out of the analyst’s predicted range.